$4.77 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 127 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 130.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTRS | Buy | VIATRIS INC | $281,072,000 | +10.2% | 20,774,000 | +10.4% | 5.90% | +18.4% |
| AHCO | Buy | ADAPTHEALTH CORP | $250,114,000 | +32.5% | 10,225,445 | +26.2% | 5.25% | +42.4% |
| Buy | GLAUKOS CORPnote 2.750% 6/1 | $242,436,000 | +87.0% | 204,700,000 | +89.5% | 5.08% | +101.0% | |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $117,360,000 | +7.1% | 1,377,945 | +20.6% | 2.46% | +15.2% |
| Buy | TABULA RASA HEALTHCARE INCnote 1.750% 2/1 | $80,473,000 | +114.9% | 97,816,000 | +117.4% | 1.69% | +130.9% | |
| ORGO | Buy | ORGANOGENESIS HLDGS INC | $78,142,000 | -26.5% | 8,456,876 | +13.3% | 1.64% | -21.0% |
| LUNG | Buy | PULMONX CORP | $75,905,000 | +3.9% | 2,366,867 | +16.6% | 1.59% | +11.7% |
| Buy | NUVASIVE INCnote 0.375% 3/1 | $74,729,000 | +38.1% | 77,859,000 | +39.5% | 1.57% | +48.4% | |
| Buy | NEVRO CORPnote 2.750% 4/0 | $68,194,000 | +95.5% | 61,000,000 | +134.6% | 1.43% | +110.0% | |
| SILK | Buy | SILK RD MED INC | $64,647,000 | +18.6% | 1,517,181 | +53.2% | 1.36% | +27.4% |
| Buy | SEMA4 HOLDINGS CORP | $62,292,000 | -40.7% | 13,966,824 | +0.9% | 1.31% | -36.3% | |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS IN | $54,521,000 | +96.9% | 5,580,456 | +584.7% | 1.14% | +111.9% |
| APR | Buy | APRIA INC | $53,979,000 | +2.5% | 1,655,795 | +16.8% | 1.13% | +10.1% |
| GKOS | Buy | GLAUKOS CORP | $51,613,000 | +73.1% | 1,161,414 | +87.6% | 1.08% | +86.1% |
| KURA | Buy | KURA ONCOLOGY INC | $49,193,000 | +13.4% | 3,513,756 | +51.8% | 1.03% | +22.0% |
| DAWN | Buy | DAY ONE BIOPHARMACEUTICALS I | $37,113,000 | -8.6% | 2,202,533 | +28.7% | 0.78% | -1.8% |
| New | XILIO THERAPEUTICS INC | $33,739,000 | – | 2,154,061 | +100.0% | 0.71% | – | |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $32,959,000 | -2.9% | 4,695,020 | +57.7% | 0.69% | +4.4% |
| New | THE ONCOLOGY INSTITUTE INC | $32,137,000 | – | 3,296,107 | +100.0% | 0.67% | – | |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $25,000,000 | – | 5,000,000 | +100.0% | 0.52% | – |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $23,353,000 | +592.6% | 1,686,140 | +618.6% | 0.49% | +642.4% |
| FIGS | New | FIGS INCcl a | $22,867,000 | – | 829,707 | +100.0% | 0.48% | – |
| BLU | New | BELLUS HEALTH INC NEW | $19,714,000 | – | 2,449,000 | +100.0% | 0.41% | – |
| PROF | Buy | PROFOUND MED CORP | $19,246,000 | +1.3% | 1,713,797 | +32.1% | 0.40% | +8.9% |
| NVRO | New | NEVRO CORP | $17,511,000 | – | 216,000 | +100.0% | 0.37% | – |
| BBIO | New | BRIDGEBIO PHARMA INCcall | $16,680,000 | – | 1,000,000 | +100.0% | 0.35% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $16,227,000 | – | 343,213 | +100.0% | 0.34% | – |
| APEN | New | APOLLO ENDOSURGERY INC | $14,753,000 | – | 1,750,000 | +100.0% | 0.31% | – |
| MRUS | New | MERUS N V | $13,897,000 | – | 437,000 | +100.0% | 0.29% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $12,909,000 | – | 88,000 | +100.0% | 0.27% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $12,697,000 | – | 141,000 | +100.0% | 0.27% | – |
| New | LIANBIOsponsored ads | $10,982,000 | – | 1,782,747 | +100.0% | 0.23% | – | |
| Buy | NYXOAH S A | $10,471,000 | +19.0% | 455,262 | +51.4% | 0.22% | +27.9% | |
| SRSA | New | SARISSA CAPITAL ACQUISITN COcl a | $9,790,000 | – | 999,999 | +100.0% | 0.20% | – |
| EUCR | New | EUCRATES BIOMEDICAL ACQU COR | $9,760,000 | – | 999,999 | +100.0% | 0.20% | – |
| New | WEAVE COMMUNICATIONS INC | $8,418,000 | – | 554,519 | +100.0% | 0.18% | – | |
| New | GUARDANT HEALTH INCnote 11/1 | $8,053,000 | – | 8,000,000 | +100.0% | 0.17% | – | |
| TMPM | New | TURMERIC ACQUISITION CORPcl a | $7,365,000 | – | 750,000 | +100.0% | 0.15% | – |
| New | HYPERFINE INC | $7,250,000 | – | 1,000,000 | +100.0% | 0.15% | – | |
| New | BENEFITFOCUS INCnote 1.250%12/1 | $6,229,000 | – | 6,500,000 | +100.0% | 0.13% | – | |
| New | PYXIS ONCOLOGY INC | $3,420,000 | – | 311,754 | +100.0% | 0.07% | – | |
| New | ROIVANT SCIENCES LTD*w exp 09/30/202 | $2,047,000 | – | 1,000,000 | +100.0% | 0.04% | – | |
| GKOS | New | GLAUKOS CORPcall | $2,009,000 | – | 45,200 | +100.0% | 0.04% | – |
| New | THE ONCOLOGY INSTITUTE INC*w exp 11/15/202 | $863,000 | – | 1,250,000 | +100.0% | 0.02% | – | |
| TMPMW | New | TURMERIC ACQUISITION CORP*w exp 10/08/202 | $170,000 | – | 250,000 | +100.0% | 0.00% | – |
| EUCRW | New | EUCRATES BIOMEDICAL ACQU COR*w exp 10/23/202 | $193,000 | – | 333,333 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.